NCT04752371View on ClinicalTrials.gov

A Study to Evaluate Camoteskimab in Participants With Still's Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Adult Onset Still's Disease
Interventions
DRUG

Camoteskimab (CERC-007, AVTX-007, AEVI-007)

Intravenous (IV) Infusion

Trial Locations (11)

9000

Sponsor Investigative Site, Ghent

21018

Sponsor Investigative Site, Vinnitsa

32610

Sponsor Investigative Site, Gainesville

36011

Sponsor Investigative Site, Poltava

46002

Sponsor Investigative Site, Ternopil

48109

Sponsor Investigative Site, Ann Arbor

82-300

Sponsor Investigative Site, Elblag

85-168

Sponsor Investigative Site, Pomorskie

61-113

Sponsor Investigative Site, Poznan

61-545

Sponsor Investigative Site, Poznan

03151

Sponsor Investigative Site, Kyiv

Sponsors
All Listed Sponsors
lead

Apollo Therapeutics Ltd

INDUSTRY